Solid GT Raises $42.5 million in Series B financing
DMD is a severe X-linked form of muscular dystrophy that affects approximately 1 in 3,600 males. DMD is caused by the absence of dystrophin, a structural protein critical for protecting skeletal and cardiac muscle against contraction-induced injury. Characterized by progressive and pervasive muscular degeneration, patients with DMD lose the ability to walk in the early to mid teens and .progress to full loss of upper body function DMD patients suffer from progressive cardiopulmonary complications which are the primary cause of mortality, typically in the early.
About Solid GT
Solid GT, a subsidiary of Solid Biosciences, is a gene therapy platform focused on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company’s licensed technology has demonstrated efficacy in various DMD animal models and lead candidates are currently undergoing ,IND-enabling studies. Founded in 2014 Solid GT is collaborating with leading patient organizations, experts, universities, hospitals .and gene therapy centers, globally.